CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 252 enrolled / 252 target
Drug / intervention
Oliceridine +1 moredrug
Likely dose
15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06411665
NCT06411665Phase 4CompletedOn Track (10.5/mo)Completion was 15mo ago

Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting in Laparoscopic Colorectal Surgery: A Randomized Trial

Peking University First Hospital·interventional·Posted May 13, 2024·Updated Jun 24, 2026

In Brief

A Phase 4 clinical trial evaluating Oliceridine and Morphine for Laparoscopic Colorectal Surgery and 4 related conditions. Completed, enrolled 252 participants across 1 site.

Detailed Summary

Postoperative nausea and vomiting (PONV) is common after surgery and impede rapid recovery after surgery. Patients who undergo laparoscopic colorectal surgery are more likely to develop PONV due to the pneumoperitoneum, interruption of gastrointestinal system, delay of oral feeding, and nasogastric catheterization, as well as postoperative opioid analgesic requirement to control acute pain. Oliceridine is a novel selective μ-opioid agonist. It stimulates G protein signalling but is markedly less potent than morphine for β-arrestin recruitment; the latter contributes to opioid-related adverse events including PONV. It is postulated that G protein-biased agonists may deliver effective analgesia with fewer opioid-related adverse events. This randomized trial aimed to investigate whether oliceridine for patient-controlled analgesia can decrease the incidence of PONV in patients recovering from laparoscopic colorectal surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedMay 13, 2024
Enrollment StartJul 2, 2024
Primary CompletionMar 14, 2025
Study CompletionApr 14, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.1 years ago

Arms & Interventions

Oliceridine groupexperimental

Patient-controlled analgesia pump is provided immediately after surgery. The pump is established with oliceridine 15 mg, diluted with normal saline to 100 ml, and programmed to deliver 2-ml boluses with a 10-min lockout interval and a background infusion rate at 1 ml/h. The pump will be used during the first 3 days after surgery.

Drug: Oliceridine
Morphine groupactive_comparator

Patient-controlled analgesia pump is provided immediately after surgery. The pump is established with morphine 50 mg, diluted with normal saline to 100 ml, and programmed to deliver 2-ml boluses with a 10-min lockout interval and a background infusion rate at 1 ml/h. The pump will be used during the first 3 days after surgery.

Drug: Morphine

Interventions

Oliceridinedrug

Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.

Morphinedrug

Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.